echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > One treatment is expected to be cured for life?

    One treatment is expected to be cured for life?

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    At present, the industry-recognized Cellular and Gene Therapy (CGT, Cellular and Gene Therapy) refers to the transfer of certain genetic material to the specific target cells of the patient, and the modification of individual gene expression or gene expression through gene addition, gene modification, gene silencing, etc.
    The process of repairing abnormal genes and achieving the purpose of curing diseases

    .
    As a new field in the treatment of cancer and genetic diseases, CGT therapy is currently a very promising development direction in the field of biomedicine

    .

    One treatment is expected to be cured for life

    One treatment is expected to be cured for life

    Unlike most traditional chemical drugs and biological macromolecular drugs that target proteins, most CGT therapies directly target DNA, and treat diseases from the source by changing DNA, aiming at some serious and rare genetic diseases that are not cureable.
    In the case that traditional medicine can only cure but cannot cure, CGT therapy has the potential to cure these diseases, and it is expected to achieve the purpose of one-time treatment and life-long recovery

    .

    Supervision and quality standards and regulations promote the development of the industry

    Supervision and quality standards and regulations promote the development of the industry

    In 2016, 21-year-old college student Wei Zexi passed away after receiving immunotherapy without regulatory approval.
    This incident revealed the lack of strict government supervision in the early stage of the development of CGT therapy, and set off a domestic reflection on immunotherapy, which also prompted the Chinese government A 19-month ban was imposed on the research and clinical application of CGT therapy

    .

    After this incident, led by the National Health Commission and the National Medical Products Administration, the reform of the domestic policy side was fully launched
    .
    At the end of 2017, a priority review channel was opened for drugs for the treatment of rare or life-threatening diseases.
    A variety of CAR-T therapies have been included in the priority approval list; at the beginning of 2019, the National Health Commission has standardized the application of new biomedical technologies in clinical trials.
    Soliciting opinions, the division of labor has clarified the responsibilities of the National Health Commission and the local health commissions.
    High-risk research is approved by the former, and medium- and low-risk research is approved by the latter.
    In April 2019, domestic clinical research and translation of in vivo cell therapy The application of management methods for soliciting opinions has opened the way for cell therapy to be included in the strict clinical supervision and record management track

    .

    The introduction of a series of domestic industry regulatory policies and treatment standards has gradually strengthened and improved the industry regulatory work in the field of CGT treatment, and also put forward specific and feasible technical requirements for the development of the industry.
    This is consistent with the general trend of global CGT treatment supervision.
    Promoted the development of the domestic CGT industry

    .

    Product form of CGT therapy

    Product form of CGT therapy

    Specific to the product form, CGT therapy includes plasmid DNA, viral vectors, bacterial vectors, human gene editing technology, patient-derived cells, and gene therapy products
    .

    Source: public data compilation

    The carrier is the most important part of CGT therapy

    The carrier is the most important part of CGT therapy

    It is particularly noteworthy that the carrier is the most important link in cell gene therapy
    .
    Whether it is in vivo or in vitro therapy, vectors are indispensable: in in vivo therapy, it is necessary to deliver the therapeutic gene to the patient through a viral or non-viral vector; in in vitro therapy, the patient’s cells need to be in vitro Return after genetic modification

    .

    The development and production of CGT therapy mainly includes three links: plasmid production, viral vector production, and cell preparation
    .
    At the level of preparation and application technology, plasmid production technology has been developed for many years, the production process is very mature, and the difficulty is relatively small; at present, viral vectors are the mainstream vector for clinical trials of gene therapy products.
    According to statistics, more than 2/3 of clinical trials have selected them.
    Viruses are used as vectors.
    Among them, the most widely used viral vectors include retroviruses and lentiviruses, adenoviruses, and adeno-associated viruses

    .
    Viral vectors have individualized needs.
    The diversity and complexity of preparation have increased the difficulty of production, and the current preparation costs are extremely high.
    The supply of viral vectors has become a bottleneck for the entire industry

    .

    According to rough statistics, plasmids and viral vectors account for half of the current CGT treatment field
    .

    Abundant reserves of products under research are waiting for the industry to break out

    Abundant reserves of products under research are waiting for the industry to break out

    CGT therapy is gradually transforming from basic scientific research to industrial application, and it is also widely recognized and valued by the market
    .

    According to reports, in the future, a large number of cell and gene therapy research projects will begin to focus on entering the clinical stage.
    It is expected that by 2026, there will be more than 8,000 cell therapy clinical pipelines and more than 3,000 gene therapy clinical pipelines.
    The entire CGT industry will be in the future.
    It is expected to achieve a ten-fold increase in the past 5 years

    .
    As early as 2019, the FDA issued a statement stating that in view of the surge in the number of CGT therapies entering the preclinical stage, the FDA expects that by 2025, 10 to 20 CGT products will be approved each year

    .

    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.